CJC-1295: separating mechanism from outcome
A framework for evaluating performance claims without treating a biological mechanism as proof of benefit.
Educational information only — not medical advice. This material cannot diagnose a condition, recommend treatment, or replace care from a qualified clinician who knows your history. The Peptide Center uses an evidence-first editorial process that prioritizes primary regulatory sources, trial registries, and peer-reviewed research; uncertainty and evidence limits should be part of every health claim.
CJC-1295 is an investigational peptide and has no FDA-approved therapeutic use. A proposed effect on a biological pathway does not establish a meaningful health or performance outcome. Products marketed for human use are unapproved products.
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
CJC-1295 No DAC
An evidence-first reference for reading claims and source material about CJC-1295 No DAC.
Open resourcePeptide briefCJC-1295 No DAC / Ipamorelin
An evidence-first reference for reading claims and source material about CJC-1295 No DAC / Ipamorelin.
Open resourcePeptide briefCJC-1295 With DAC
An evidence-first reference for reading claims and source material about CJC-1295 With DAC.
Open resourcePeptide briefCJC-1295: separating endocrine research from outcome claims
How to assess research on a growth-hormone–releasing hormone analogue without overreading biomarker changes.
Open resourcePeptide briefFollistatin 344
An evidence-first reference for reading claims and source material about Follistatin 344.
Open resourceArticleWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resource